Skip to main content

Table 1 Inclusion and exclusion criteria for the CV-CORT-EX study

From: Rationale and design of the cardiovascular status in patients with endogenous cortisol excess study (CV-CORT-EX): a prospective non-interventional follow-up study

Inclusion criteria:
• Patients with the initial, recurrent or former diagnosis of endogenous CS of any aetiology:
 - ACTH-dependent CS (i.e. due to a pituitary adenoma or an ectopic tumour)
 - ACTH-independent CS (i.e. due to an adrenal adenoma or hyperplasia)
• Patients with MACE, defined as the combination of an adrenal mass and a pathological 1-mg-DST serum cortisol of ≥1.8 μg/dl, but noclinical evidence of overt CS
• Age ≥ 18 years
• Written informed consent
Exclusion criteria:
• Current glucocorticoid pharmacotherapy (except hydrocortisone substitution therapy, usually applied after surgery for CS) or systemic glucocorticoid pharmacotherapy for > 12 months within the previous 3 years
• Structural heart disease or chronic heart failure (NYHA > II)
• Organ disease potentially affecting cardiac function
• ECOG status > 2
• Former or ongoing malignant diseases (including adrenocortical cancer) treated with (potentially) cardiotoxic therapy
• Arterial hypertension (uncontrolled despite > 3 antihypertensive drugs)
• Pregnancy
• Incompliance suspected or demonstrated
• Chronic renal failure (MDRD < 60 ml/min)
  1. Abbreviations: ACTH adrenocorticotropic hormone, CS Cushing’s syndrome, DST dexamethasone suppression test, ECOG Eastern Co-operative Oncology Group, MACE mild autonomous cortisol excess, MDRD modification of diet in renal disease, NYHA New York Heart Association